The company said it was formed in June 2020 and this week is emerging from "stealth mode" to highlight its line of viral transport media and collection kits, as well as classic culture media.

The firm said that in its early launch period it is focusing on the provision of high-volume media and supplements needed in the battle against COVID-19. Supply chain disruptions have been problematic throughout the pandemic, leaving life scientists to grapple with media shortages.

Fujifilm invests $2B on cell culture manufacturing
Fujifilm plans to invest more than $2 billion to build a large-scale cell culture manufacturing site for biopharmaceuticals in the U.S.

Plastics manufacturer produces new cell culture microfilm
Toyoda Gosei, a manufacturer of rubber and plastic automotive components, has developed a urethane microfoam film for cell culture that allows cells to...

Are SARS-CoV-2 mutations more contagious than the original virus?
The SARS-CoV-2 virus has accumulated genetic mutations that may make it more contagious and more easily spread in metropolitan communities, according...

COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the...